Recommendations made by the PBAC – December 2021 intracycle meeting

28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of drugs on the PBS ...

Read more →

FDA enforces ClinicalTrials.gov results posting requirements, including threats of financial penalty

27 January 2022 - Clinical trials requiring registration on ClinicalTrials.gov generally must have results submitted no later than one year after ...

Read more →

2022 April price disclosure cycle – indicative prices

27 January 2022 - Indicative 1 April 2022 prices resulting from the 2022 April Cycle of Price Disclosure have now been ...

Read more →

ICER releases draft evidence report on novel agents to prevent chemotherapy-induced neutropenia

25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...

Read more →

Method paper: new version 6.1 comes into force

24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...

Read more →

EMA publishes agenda for 24-27 Jan CHMP meeting

23 January 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

COVID-19 vaccines and treatments: we must have raw data, now

19 January 2022 - Data should be fully and immediately available for public scrutiny ...

Read more →

National Medicines Policy Review – publication of submissions

21 January 2022 - On 30 August 2021, the National Medicines Policy Review Committee invited submissions to support the Review of ...

Read more →

Advancing health through innovation: new drug therapy approvals 2021

13 January 2022 - The FDA’s Center for Drug Evaluation and Research has issued its report, Advancing Health Through Innovation: New ...

Read more →

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations

11 January 2022 - The new CHEERS 2022 statement replaces previous CHEERS reporting guidance.  ...

Read more →

PBAC Public Summary Documents – September 2021 meeting (first time rejections and deferrals)

14 January 2022 - The Public Summary Documents (first time rejections and deferrals) from the September 2021 PBAC meeting are now ...

Read more →

ICER publishes evidence report on tirzepatide for type 2 diabetes

6 January 2022 - Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as ...

Read more →

Updated agenda for the March 2022 PBAC meeting

5 January 2022 - The agenda for the March 2022 PBAC meeting has been updated.  ...

Read more →

Public Summary Documents – September 2021 PBAC meeting

24 December 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the September 2021 PBAC ...

Read more →

PBS expenditure and prescriptions report 2020-21

24 December 2021 - The PBS Expenditure and Prescriptions Report 1 July 2020 to 30 June 2021 is now available. ...

Read more →